Convoy Therapeutics Granted Patent for Proprietary SPACE Technology

Share Article

Patent furthers development of the Convoy platform technology towards multiple uses in the field.

Transforming the Delivery of Macromolecules into the Skin

Convoy Therapeutics, Inc. is proud to announce that the United States Patent and Trademark Office has granted a patent for the proprietary Skin Permeating And Cell Entering (SPACE) Peptide technology. The company obtained a worldwide exclusive license to in 2011 from University of California at Santa Barbara.

“The granting of this patent furthers the advancement of our technology and its many uses in the field,” states Dr. John Muraski, President and CEO of Convoy Therapeutics and its parent company ACTUS Biotechnologies, Inc. The company is currently working with a number of cosmetic and pharmaceutical partners to take advantage of its platform technology with a variety of molecules. Furthermore, Dr. Muraski states, “Our platform can be adapted to various active ingredients to enable penetration of large molecules past the outer layer of the skin and into the epidermis and dermis, and there is evidence that it can also enhance retention of some small molecules.” The recent addition of a team of professionals with substantial experience in the dermatology industry has expanded the capabilities of the company as they seek to market two reformulations in the coming 12-36 months: a high molecular weight topical Hyaluronic Acid cosmetic for the reduction of fine lines and wrinkles and Cyclopsorb™, a topical cyclosporine for the treatment of moderate to severe psoriasis.

The company’s Topical Hyaluronic Acid is a cosmetic application intended to maintain a smooth complexion between filler or toxin injections while being passively absorbed into the skin, reaching the epidermal and dermal layers. Convoy is currently completing safety studies and scale up. The company has an expected launch date for their Topical Hyaluronic Acid product in Q3, 2014.

Convoy’s second product, Cyclopsorb™, for the topical treatment of moderate to severe psoriasis, is currently in the final stages of formulation to optimize long-term stability for scale up and completion of non-clinical toxicology. With written confirmation from the FDA that the 505(b)(2) pathway is appropriate for this product, the company anticipates a market launch in Q3, 2016.

The Convoy delivery platform represents a major leap forward in the topical delivery of active compounds. Convoy’s platform can potentially be used in dermatological products for the treatment of skin cancers, skin care and cosmetics, cosmeceuticals, and the reformulation of existing molecules for better penetration and retention in the skin.

Convoy Therapeutics is a subsidiary of the ACTUS Biotechnologies accelerator, an organization dedicated to accelerating innovative novel technologies to commercialization. The company was founded in 2011 based upon technology originally developed by Dr. Samir Mitragotri and his laboratory at the University of California Santa Barbara. More information can be found at http://www.convoytx.com. Information about ACTUS Biotechnologies can be found at http://www.actusbiotech.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Dr. John Muraski
Follow us on